US Patent

US11033521 — Levodopa fractionated dose composition and use

Method of Use · Assigned to AVION PHARMACEUTICALS LLC · Expires 2039-03-28 · 13y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating Parkinson's disease using a new carbidopa/levodopa pharmaceutical unit form that mimics continuous intravenous treatment.

USPTO Abstract

There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.

Drugs covered by this patent

Sinemet Cr (CARBIDOPA) · Aton

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-219`	—	Sinemet Cr

Patent Metadata

Patent number: US11033521
Jurisdiction: US
Classification: Method of Use
Expires: 2039-03-28
Drug substance claim: No
Drug product claim: Yes
Assignee: AVION PHARMACEUTICALS LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.